Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio) disclosed continued execution of its shareholder return strategy, repurchasing 747,800 shares under its general mandate up to 18 May 2026. The aggregate outlay reached HK$34.17 million, and the repurchased shares have been placed in treasury. Management reiterated that the programme underlines confidence in the company’s long-term fundamentals and will proceed subject to market conditions.

Recent inflows have bolstered Jacobio’s balance sheet. The group has collected a US$100.00 million upfront payment from its strategic collaboration with AstraZeneca and an RMB8.55 million royalty from Allist covering June–December 2025 sales. Including these receipts, cash and bank balances, capital-protected structured deposits and committed credit lines total approximately RMB2.10 billion, providing a cash runway of at least four years based on current spending plans.

The board stated that ample liquidity, a progressing oncology pipeline and collaborations with multinationals underpin the company’s view that its market valuation does not yet capture its intrinsic or commercial potential. Jacobio intends to keep monitoring market conditions and may deploy further share buy-backs under the existing mandate.